Biomea Fusion (BMEA) Total Liabilities (2020 - 2026)
Biomea Fusion (BMEA) posted Total Liabilities of $27.7 million for Q1 2026, down 4.67% sequentially from $29.0 million in Q4 2025, and up 5.12% YoY from $26.3 million in Q1 2025.
Biomea Fusion (BMEA) Total Liabilities (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Total Liabilities for 7 years, with the latest figure at $27.7 million in Q1 2026.
- Quarterly Total Liabilities rose 5.12% year-over-year to $27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.7 million (up 5.12% YoY) and the FY2025 annual result came in at $29.0 million, up 2.31% from the prior year.
- Total Liabilities eased to $27.7 million in Q1 2026 per BMEA's latest filing, from $29.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $45.7 million in Q2 2025 and troughed at $10.1 million in Q1 2022.
- A 5-year average of $27.2 million and a median of $28.4 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 200.03% in 2022, then dropped 20.68% in 2025.
- Over 5 years, Total Liabilities stood at $20.8 million in 2022, then soared by 47.78% to $30.7 million in 2023, then dropped by 7.58% to $28.4 million in 2024, then advanced by 2.31% to $29.0 million in 2025, then slipped by 4.67% to $27.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $27.7 million, $29.0 million, and $39.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 24.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.74 Mn |
| Mar 31, 2026 | 27.67 Mn |
| Dec 31, 2025 | 29.02 Mn |
| Sep 30, 2025 | 39.57 Mn |
| Jun 30, 2025 | 45.65 Mn |
| Mar 31, 2025 | 26.32 Mn |
| Dec 31, 2024 | 28.37 Mn |
| Sep 30, 2024 | 34.45 Mn |
| Jun 30, 2024 | 32.22 Mn |
| Mar 31, 2024 | 33.18 Mn |
| Dec 31, 2023 | 30.69 Mn |
| Sep 30, 2023 | 25.48 Mn |
| Jun 30, 2023 | 24.37 Mn |
| Mar 31, 2023 | 29.51 Mn |
| Dec 31, 2022 | 20.77 Mn |
| Sep 30, 2022 | 14.42 Mn |
| Jun 30, 2022 | 11.35 Mn |
| Mar 31, 2022 | 10.10 Mn |
| Dec 31, 2021 | 6.92 Mn |
| Sep 30, 2021 | 8.07 Mn |